No Priors Ep. 140 | With Benchling Co-Founder and CEO Sajith Wickramasekara
Sajith Wickramasekara, CEO of Benchling, discusses the broken economics of drug development, where high costs and failure rates stifle innovation. He explains how the biotech industry is facing a 'dot com' bust and new competition from China, and argues that AI agents and simulation can provide the solution by making science less artisanal and helping scientists create better molecules through faster, cheaper experiments.
